Memantine Hydrochloride Tablet
Product Images NDC 71335-1899

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1899). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine-figure1 (Memantine Figure1)

A line graph depicting the mean change from baseline (± SEM) in ADCS-ADL scores over 28 weeks of treatment. Two lines show data for placebo and Memantine Hydrochloride groups, with placebo showing a greater decline and Memantine Hydrochloride showing less decline over time. The y-axis ranges from clinical improvement to clinical decline; the x-axis is labeled in weeks of treatment at 0, 4, 12, and 28.*

FDA Label Image

Memantine-figure3 (Memantine Figure3)

A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine Hydrochloride and placebo. The X-axis represents weeks of treatment (0, 4, 12, 28), and the Y-axis measures mean (± SEM) change in SIB score from -12 to 4. Placebo shows a declining trend indicating clinical decline, while Memantine Hydrochloride shows stability or slight improvement, indicating less clinical decline.*

FDA Label Image

Memantine-figure5 (Memantine Figure5)

A line graph comparing changes from baseline in ADCS-ADL scores over 24 weeks of treatment. The graph shows two lines representing Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups, with error bars indicating variability. The y-axis measures mean change from baseline, and the x-axis shows weeks of treatment, with annotations indicating clinical improvement and decline.*

FDA Label Image

Memantine-figure7 (Memantine Figure7)

A line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment comparing Memantine Hydrochloride/Donepezil and Placebo/Donepezil groups. The y-axis shows the mean change with error bars (± SEM), ranging from clinical decline to clinical improvement. The x-axis represents weeks of treatment from 0 to 24. Two lines represent the treatment groups, with Memantine Hydrochloride/Donepezil showing an upward trend indicating improvement, while Placebo/Donepezil shows a downward trend indicating decline.*

FDA Label Image

Memantine_structure (Memantine Structure)

Chemical structure diagram of Memantine Hydrochloride showing its molecular framework with labeled functional groups including NH2 and HCl components.*

FDA Label Image

Label (Lbl713351899)

Label for Memantine HCl 10 mg Tablet from Bryant Ranch Prepack, available in a package of 30 tablets. The label states to compare to Namenda 10 mg Tablet by Ajanta Pharma Limited. The package is identified with NDC 71335-18991 and includes storage instructions to keep at 20°-25°C (68°-77°F) and to keep all drugs out of reach of children. The label also identifies the product as prescription only and notes a gray capsule imprinted with 'm10'.*

FDA Label Image

Memantine-figure2 (Memantine Figure2)

A cumulative percentage of patients chart comparing placebo and memantine hydrochloride groups. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients. The memantine hydrochloride group curve lies above the placebo group, indicating a higher cumulative percentage of patients achieving various ADCS-ADL changes.*

FDA Label Image

Memantine-figure4 (Memantine Figure4)

A line graph displaying cumulative percentage of patients versus SIB change from baseline, comparing Memantine Hydrochloride to placebo. The horizontal axis shows SIB change from -30 to 15, and the vertical axis indicates cumulative percentage from 0 to 100. Memantine Hydrochloride data are represented by circles, and placebo data by squares.*

FDA Label Image

Memantine-figure6 (Memantine Figure6)

A cumulative percentage graph comparing the effects of Memantine Hydrochloride/Donepezil versus Placebo/Donepezil on patient outcomes, shown as ADCS-ADL change from baseline. The x-axis represents change from baseline and the y-axis shows cumulative percentage of patients.*

FDA Label Image

Memantine-figure8 (Memantine Figure8)

A cumulative percentage plot showing the change from baseline in SIB (Severe Impairment Battery) scores for patients treated with either Memantine Hydrochloride/Donepezil or Placebo/Donepezil. The x-axis represents the change from baseline in SIB score, and the y-axis shows the cumulative percentage of patients. Two curves compare the treatments over a range of score changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.